Cure My Disease

Don't miss your cure!

 Log in / Sign up

Safer syringe program aims to cut infections in drug users worldwide

NCT ID NCT06395129

Knowledge-focused Sponsor: Médecins du Monde Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether giving out special syringes with less leftover space (low dead-space) can help reduce the spread of HIV and hepatitis among people who inject drugs. Researchers will talk with participants and track their health in several countries. The goal is to find the best way to run these programs and make them more acceptable and effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

People aged 18+ who report injecting drug use

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥18 years (note that country-specific protocols may include participants aged ≥16 where appropriate and relevant); * Reporting a history of recent (past month) injection drug use; * Accessing the NSP to receive injecting equipment at either a facility, mobile service or through outreach and have an accompanying assigned program unique ID; * Able to understand and communicate in the local language(s); * If self-reporting HCV/HIV negative status, interested in and agreeing to undergo HCV and HIV testing; and * Willing and able to provide informed consent to take part in the study. Exclusion Criteria: * N/A

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug use are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS Harm Reduction hepatitis HIV infectious disease substance abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug use Hepatitis HIV

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hepa+

    RECRUITING

    Tbilisi, Georgia

  • Mefada

    RECRUITING

    Kinondoni, Tanzania

  • Mukikute

    RECRUITING

    Dar es Salaam, Tanzania

  • New Vector

    RECRUITING

    Rustavi, Georgia

  • Peer 2 Peer

    RECRUITING

    Dar es Salaam, Tanzania

  • Real World Real People

    RECRUITING

    Yerevan, Armenia

  • STEPS Tanzania

    RECRUITING

    Ubungo, Tanzania

  • Step to Future

    RECRUITING

    Gori, Georgia

  • Yovaribe

    RECRUITING

    Ilala, Tanzania

More trials for these conditions

Other studies related to the condition(s) this trial covers.